louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06998953: Social Isolation But Not Deprivation Involved in Employment Status After Bariatric Surgery.
Official title: Social Isolation But Not Deprivation Involved in Employment Status After Bariatric Surgery.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bariatric Surgery
Weight Loss
Employment
Obesity
Lead sponsor: Centre Hospitalier de Saint-Denis
Sponsor class: OTHER
First posted: 2025-05-31
Enrollment: 133
Sex: ALL
Minimum age (years): 18
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consists of adults who underwent bariatric surgery, predominantly sleeve gastrectomy, in a socioeconomically deprived area. Participants were selected retrospectively and evaluated at an average of 2.3 years post-surgery. The group included 133 individuals, with a majority being women (approximately 88%), and an average age of 45 years (range: 19-67 years). All participants completed standardized questionnaires assessing deprivation (EPICES score), quality of life and social factors (BAROS score), and satisfaction with outcomes. The population is characterized by severe obesity prior to surgery (mean BMI of 42.7 kg/m²).

Brief summary: This study looked at how bariatric surgery (weight-loss surgery) affects people's chances of getting a job, especially in a low-income area. Researchers followed 133 patients (mostly women, average age 45) about 2 years after their surgery. Most had a type of surgery called sleeve gastrectomy and lost a significant amount of weight.

They found that 19 people got a job after surgery, but 3 also became unemployed. People who were already employed before surgery had better results on satisfaction and well-being scores. Interestingly, finding a new job after surgery wasn't linked to weight loss, age, or sex. Also, being poor (measured by the EPICES score) didn't affect employment outcomes. However, people who felt more socially isolated were less likely to lose weight successfully.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent bariatric surgery (mainly sleeve gastrectomy).
* Follow-up duration of approximately 2.3 ± 0.1 years after surgery.
* Residing in a deprived area (context of the study).
* Adults (participants were aged between 18 and 67 years).

Exclusion Criteria:

* Patients who did not undergo bariatric surgery.
* Missing or incomplete data (e.g., unanswered questionnaires).
* Patients outside the follow-up period (less or more than 2.3 years post-surgery).
* Possibly: Minors (\<18 years old).

Primary outcomes:
measure: Change in employment status after bariatric surgery
timeFrame: January 2020 - June 2020
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-Denis
country: France
facility: France
Study officials:
References:
Clinical trial NCT03787953: A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
Official title: A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Advanced Solid Tumors
Keywords: anti-PD-1/PD-L1 antibodies
Efficacy
Safety
Real world study
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
Collaborators: name: LinkDoc Technology (Beijing) Co. Ltd.
First posted: 2018-12-27
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy

Brief summary: The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.

Detailed description: The study is a real-world study and the case records of patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy will be collected in this study. The medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to analyze the effectivity and safety of anti-PD-1/PD-L1 antibodies and explore the prognosis-relevant factors of advanced solid tumors.

Eligibility criteria: Inclusion Criteria:

* Pathologically or cytologically confirmed advanced solid tumors;
* Received anti-PD-1/PD-L1 antibody therapy.

Exclusion Criteria:

* No specific exclusion criteria in this real world study.

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: 6 months
Secondary outcomes:
measure: Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with advanced solid tumors receiving anti-PD-1/PD-L1 antibody therapy.
timeFrame: up to 4 weeks after the last dose
measure: Objective Response Rate (ORR)
timeFrame: 6 months
measure: Disease Control Rate (DCR)
timeFrame: 6 months
measure: Overall survival (OS)
timeFrame: up to 12 months
Other outcomes:
measure: Biomarkers
timeFrame: before the first dose
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
Study officials:
affiliation: Chinese PLA General Hospital
name: Shunchang Jiao, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05297253: Prosthetic and Biological Complications of Implant Supported Prostheses
Official title: Prosthetic and Biological Complications of Implant Retained Fixed Versus Removable Telescopic Overdentures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Implant Complication
Keywords: dental implant prosthesis
completely edentulous
Lead sponsor: National Research Centre, Egypt
Sponsor class: OTHER
First posted: 2022-03-28
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: completely edentulous patients

Brief summary: complications of implant retained prostheses

Detailed description: counting and analyzing the prosthetic and biological complications of the fixed and removable implant retained prostheses in the completely edentulous patients

Eligibility criteria: Inclusion Criteria:

* completely edentulous patients

Exclusion Criteria:

* medically free adequate bone quality and quantity

Primary outcomes:
measure: biological complications
timeFrame: one month
Secondary outcomes:
measure: prosthetic complications
timeFrame: three months after delivery of the prostheses
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: National Research Centre
Study officials:
References:
Clinical trial NCT01091753: Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers
Official title: Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: Non-dipper HTN patient
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-03-24
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of nocturnal administration of Anti-hypertensive medications in Non-dippers.

Efficacy variables.

1. ECHO
2. 24hr. horter
3. IMT
4. BUN/crea, urine analysis (microalbulinuria
5. Cardio vascular event. "


Eligibility criteria: Inclusion Criteria:

1. Essential hypertension (stage 1-2)
2. 24hr. holer : non-dipper
3. Age 18 \~70.

Exclusion Criteria:

1. Any known malignant disease
2. Renal failure , creatinine \>2.0mg/dl
3. Liver disease

Primary outcomes:
measure: IMT(intima media thickness) Measure data(Sono)
timeFrame: baseline
measure: IMT(intima media thickness) Measure data(Sono)
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University College of Medicine
Study officials:
affiliation: professor of division of Cardiology
name: Dong hun Choi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02419053: Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children
Official title: Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intraoperative Complications
Postoperative Complications
Keywords: Surgical safety checklist
perioperative complications
pediatric
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
Collaborators: name: Institute for Clinical Evaluative Sciences
First posted: 2015-04-17
Enrollment: 28772
Sex: ALL
Minimum age (years): 28
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Surgical interventions performed in Ontario for children

Brief summary: The purpose of this study is to see if the surgical safety checklist is associated with a reduction in perioperative complications for children undergoing surgery in Ontario, Canada.


Eligibility criteria: Inclusion Criteria:

* Surgical admission, with a noncardiac surgical interventions
* Aged between \>28 days and \<18years on the day of the surgical intervention

Exclusion Criteria:

* Non-surgical admission
* Surgical interventions with \<10 per group
* Cardio-thoracic and interventional cardiology procedures

Primary outcomes:
measure: Perioperative complications
timeFrame: 30-days after surgery
Secondary outcomes:
measure: Healthcare utilization - proportion of Emergency Room visits
timeFrame: 30-days after surgery
measure: Healthcare utilization - rate of unplanned return to the operating room
timeFrame: 30-days after surgery
measure: Healthcare utilization - length of hospital stay
timeFrame: 30-days after surgery
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Hospital for Sick Children
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children, Toronto
name: James D O'Leary, MBBCh
role: PRINCIPAL_INVESTIGATOR
References:
citation: O'Leary JD, Wijeysundera DN, Crawford MW. Effect of surgical safety checklists on pediatric surgical complications in Ontario. CMAJ. 2016 Jun 14;188(9):E191-E198. doi: 10.1503/cmaj.151333. Epub 2016 Mar 14.
Clinical trial NCT00359853: Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
Official title: Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Spontaneous Bacterial Peritonitis
Hepatorenal Syndrome
Cirrhosis
Keywords: Norfloxacin, primary prophylaxis, SBP
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
First posted: 2006-08-03
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Advanced liver disease and low ascitic fluid protein concentration have been identified as risk factors for spontaneous bacterial peritonitis in cirrhosis. Moreover, renal impairment and hyponatremia increase mortality rate of this infection. Aims: To investigate if oral administration of norfloxacin prevents the first episode of SBP, hepatorenal syndrome and improves survival in cirrhotic patients with ascites and low protein concentration in ascitic fluid (\<15 g/L) and at least one of the following inclusion criteria: functional renal failure (serum creatinine ≥ 1,2 mg/dl or BUN ≥ 25 mg/dl), hyponatremia (serum sodium ≤ 130 mEq/L) or advanced liver disease (Child ≥ 9 points with serum bilirubin ≥ 3 mg/dl). Methods: Prospective, multicenter, randomized, double-blind placebo controlled trial comparing oral norfloxacin (400 mg/d; n=35) with placebo (n=35).


Eligibility criteria: Inclusion Criteria:

* Age 18-80 years, protein concentration in ascitic fluid \< 15 g/L and at least one of the following: serum creatinine ≥ 1.2 mg/dl or BUN ≥ 25 mg/dl, serum sodium ≤ 130 mEq/L or severe liver failure as defined by a Child-Pugh score ≥ 9 points and a serum bilirubin ≥ 3 mg/dl.

Exclusion Criteria:

* Previous history of spontaneous bacterial peritonitis or of norfloxacin prophylaxis, allergy to quinolones, hepatocellular carcinoma, organic renal failure and HIV infection

Primary outcomes:
measure: Short-term and long-term survival
Secondary outcomes:
measure: Prevention of the first episode of spontaneous bacterial peritonitis
measure: Prevention of hepatorenal syndrome
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clinic Barcelona
state: Catalonia
Study officials:
affiliation: Liver Unit. Hospital Clinic Barcelona
name: Miquel Navasa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04183153: Neuroendocrine Mapping of the Cerebral Cortex
Official title: Endo-Connectome Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Healthy
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2019-12-03
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study is investigating brain regions that share functional connectivity with the hypothalamus and the stimulation of those regions using repetitive transcranial magnetic stimulation (rTMS) to activate the hypothalamus indirectly. The goal of this study is to determine the effectiveness of rTMS in influencing the hypothalamus to better understand the mechanisms between it and the neuroendocrine processes it controls.


Eligibility criteria: Inclusion Criteria:

* Age: 21-55
* Gender: Females and Males
* Weight: Less than 280 pounds
* Mobile
* Normal vision with corrective lenses if necessary
* Fluent in English (written and spoken)

Exclusion Criteria:

* History of epilepsy/seizures (including history of withdrawal/provoked seizures)
* Metal implant in brains (e.g. deep stimulation), cardiac pacemaker, or cochlear implants
* Shrapnel or any ferromagnetic item in the head
* Showing symptoms of withdrawal from alcohol or benzodiazepines
* Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)
* Migraine or significant headaches
* Shoulder or neck stiffness
* Over 280 pounds
* In-dwelling ferrous metals
* Left handed
* Abnormal hearing
* Abnormal vision that cannot be corrected with lenses
* Claustrophobia
* Illicit drug use
* Psychotropic medication use
* Marijuana and/or nicotine use
* Psychiatric or neurological conditions
* Endocrine conditions
* History of head trauma with loss of consciousness

Primary outcomes:
measure: Plasma GnRH levels resulting from hypothalamus activation via LC-MS
timeFrame: 3 hours
measure: Plasma vasopressin levels via LC-MS
timeFrame: 3 hours
measure: Plasma oxytocin levels via LC-MS
timeFrame: 3 hours
measure: Plasma TRH levels via LC-MS
timeFrame: 3 hours
measure: Plasma CRH levels via LC-MS
timeFrame: 3 hours
measure: Plasma somatostatin levels via LC-MS
timeFrame: 3 hours
measure: Plasma PRLH levels via LC-MS
timeFrame: 3 hours
measure: Plasma FSH levels via LC-MS
timeFrame: 3 hours
measure: Plasma LH levels via LC-MS
timeFrame: 3 hours
measure: Plasma ACTH levels via LC-MS
timeFrame: 3 hours
measure: Plasma cortisol levels via LC-MS
timeFrame: 3 hours
Secondary outcomes:
measure: Blood pressure via sphygmomanometer
timeFrame: 3 hours
measure: Heart rate via pulse oximeter
timeFrame: 3 hours
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Keith Sudheimer, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04549753: A Study on Brain Activity During Transcranial Direct Current Stimulation in Stroke Patients
Official title: A Study on Brain Activity During Transcranial Direct Current Stimulation for Improving Finger-Hand Function in Stroke Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2020-09-16
Enrollment: 30
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to identify the characteristics of neural plasticity seen in stroke patients by measuring the changes in brain activity during stimulation using functional near-infrared spectroscopy (fNIRS) when applying transcranial direct current stimulation (tDCS) for the purpose of enhancing finger function.


Eligibility criteria: Inclusion Criteria:

* Unilateral stroke patients
* Chronic patients over 6 months after onset
* Subcortical stroke
* Patients with the movement of fingers

Exclusion Criteria:

* History of psychiatric disease
* Significant other neurological diseases except for stroke
* Difficult to perform this experiment
* Patients with metal implants
* History of epilepsy
* Pregnancy
* Skin defect at the site of electrode attachment

Primary outcomes:
measure: Changes in cortical activity using fNIRS signals during brain stimulation
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
Secondary outcomes:
measure: Changes in motor evoked potential
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
measure: 9-hole pegboard test
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
measure: Grip & Tip pinch strength test
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
measure: Box & Block test
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
measure: Fugl-Meyer Assessment
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
measure: Finger tapping test
timeFrame: Baseline and about 10 days (immediately after brain stimulation sessions)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
Clinical trial NCT06077253: Danish Angle Closure Prevention Trial
Official title: Danish Angle Closure Prevention Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Primary Angle Glaucoma Closure Suspect
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2023-10-11
Enrollment: 242
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: One eye intervention (prophylactic iridotomy), one eye no intervention
Primary purpose: PREVENTION

Brief summary: To determine whether primary angle closure suspects (PACS) in a Caucasian population benefit from prophylactic laser iridotomy.

Detailed description: Prospective, randomised paired-eye design clinical trial comparing peripheral laser iridotomy in one eye with observation in the other over 5-years follow-up.

Eligibility criteria: Inclusion Criteria:

* Primary angle closure suspect: ≥180 degrees (cumulative) irido-trabecular contact on darkroom gonioscopy, IOP\<21mmHg, no peripheral anterior synechiae, no glaucomatous optic neuropathy
* Best-corrected visual acuity (BCVA) \>0.8 on both eyes
* Caucasian

Exclusion Criteria:

* Pseudophakia
* Previous iridotomy
* Clinically significant cataract with indication for surgery,
* Gaucoma
* Uveitis
* Unstable retinal conditions
* Ocular malignancies
* PEX
* PDS
* Systemic or ocular corticosteroid treatment

Primary outcomes:
measure: Intraocular pressure
timeFrame: 5 year
measure: Glaucoma
timeFrame: 5 year
measure: Acute Primary Angle Closure
timeFrame: 5 year
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University Hospital
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
city: Glostrup
country: Denmark
facility: Rigshospitalet Glostrup
city: Odense
country: Denmark
facility: Odense University Hospital
city: Vejle
country: Denmark
facility: Sygehus Lillebælt
Study officials:
affiliation: Aarhus University Hospital
name: Niklas Telinius
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01238653: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
Official title: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Liver Cancer
Keywords: liver
cancer
tumor
Pathfinder
Lead sponsor: Pathfinder Therapeutics
Sponsor class: INDUSTRY
First posted: 2010-11-10
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any subject scheduled for a laparoscopic procedure where liver surface visualization and surface swabbing is feasible with standard port placement.

Brief summary: This study was designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic liver procedure. The hypothesis is that there will be no clinically relevant difference between the error measurements obtained during the laparoscopic procedures in this study when compared with those obtained during previous open liver registration studies.

The surface of the liver will be manually swabbed with the study tracked laparoscopic probe with landmarks noted during data collection. After registration of the liver is obtained, the registration points obtained during this procedure will be evaluated by the surgeon by moving the tracked laparoscopic probe over the liver surface and evaluating the location of the tracked laparoscopic probe displayed on the guidance system three dimensional (3D) image. The surgeon will accept or reject the registration accuracy.

Detailed description: The Pathfinder System used during this study is used for data collection purposes only and is not used during the surgical procedure as an image guided system.

Preoperative computed tomography (CT) scans, obtained as standard of care, will be used to generate the image guided liver system 3D liver surface images used during the study.

During the laparoscopic procedure, the Pathfinder device will be inserted through the standard laparoscopic ports (5mm or 10mm) being used for the staging procedure.

A total study population will include 20 subjects that complete the laparoscopic procedure scheduled.

Eligibility criteria: Inclusion Criteria:

* Scheduled for laparoscopic procedure
* Had a preoperative CT image that includes the liver

Exclusion Criteria:

* Severe cirrhosis of the liver
* Kidney failure or dialysis
* Unable to consent

Primary outcomes:
measure: The number of accurate liver surface registrations obtained in the laparoscopic environment compared to accurate liver surface registrations obtained in open procedures
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburg
country: United States
facility: UPMC, Montefiore Hospital Liver Cancer Center
state: Pennsylvania
Study officials:
affiliation: UPMC, Montefiore Hospital Liver Cancer Center
name: David A. Geller, M.D.
role: PRINCIPAL_INVESTIGATOR
References: